Study Title: ADSCaN - A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer.
Study Description: We hypothesize that sequential chemo-radiotherapy using accelerated, dose escalated radiotherapy will intensify loco-regional treatment, improve local control and overall survival compared to conventionally fractionated sequential chemo-radiotherapy treatment. This trial will take 4 dose escalated accelerated sequential chemo-radiotherapy schedules into a randomized phase II comparison with a UK standard sequential chemo-radiotherapy using state-of-the art radiotherapy. It would be impossible to test all schedules in phase III study so we will use a combined randomized phase II screening / " pick the winner " approach to select one schedule for further testing in a randomized phase III study.
Study Design: Randomised phase II screening/ "pick-the-winner " design to select a single regimen to go forward for phase III testing. A novel design will be used that will allow individual centres to randomise to only one (but more if they have the resource) of the experimental schedules.
Trial Status: In Set Up
Chief Investigator:
Professor Matthew Hatton, Consultant and Honorary Reader in Oncology,
Weston Park Hospital, Whitham Road,
Sheffield, S10 2SJ
Sponsor: NHS Greater Glasgow Clyde
Date Opened: 22nd August 2017
Planned Closure Date: April 2021
Target Recruitment: 360 patients
Open to New Sites: Yes
Contact Details:
Project Manager:
Claire Lawless
Project Manager
CRUK Clinical Trials Unit
The Beatson West of Scotland Cancer Centre
Level 0, 1053 Great Western Road,
Glasgow, G12 0YN
Tel: 00 44 (0) 141 301 7947
Fax: 00 44 (0) 141 301 7946
E-mail: [email protected]
Clinical Trial Co-ordinator:
Ann Shaw
Clinical Trial Coordinator
CRUK Clinical Trials Unit
The Beatson West of Scotland Cancer Centre
Level 0, 1053 Great Western Road,
Glasgow, G12 0YN
Tel: 00 44 (0) 141 301 7952
Fax: 00 44 (0) 141 301 7946
E-mail: [email protected]
Click here to download the Initiation Slides
For queries concerning safety reporting and the identification of unexpected events related to radiotherapy administration please contact:
The Pharmacovigilance Team email: [email protected] or
Telephone: 0141 211 0352/0203/3567/3968 or 0141 232 2068
Version of NCI Common Terminology Criteria for Adverse Events (CTCAE) being used for the study: 4.03
Click here to download the CTCAE
